Clinical Trial Update: Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Clinical trial update indicates a Phase 2 neoadjuvant study of iParomlimab and Tuvonralimab (QL1706) in hormone receptor-positive, HER2-negative breast cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: RenJi Hospital | Conditions: Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING